Navigation Links
PharmAthene and Panacea Biotec Ltd. Establish Strategic Alliance in Biodefense and Emerging Infectious Diseases
Date:9/30/2008

r human health needs."

"An alliance with PharmAthene presents important strategic opportunities to create value for both of our companies," said Mr. Rajesh Jain, Joint Managing Director of Panacea Biotec. "Panacea Biotec is committed to identifying partners for US distribution of our products. We recognize PharmAthene's strength in the biodefense space and the core competencies of its management team with respect to vaccine development and commercialization. We are very pleased to participate in this strategic alliance."

Under a related agreement, PharmAthene has the first right of negotiation for US distribution of certain of Panacea Biotec's biodefense products and may enter into discussions with Panacea Biotec regarding potential strategic collaborations that could include development and manufacturing by Panacea Biotec of certain PharmAthene biodefense products.

The investment will increase PharmAthene's ongoing product development activities, enhance working capital, and provide new resources for corporate growth. Immediately after the closing Panacea Biotec, through its subsidiary, will own approximately 14.5% of PharmAthene's issued and outstanding common stock and, with the warrant, will have the right to purchase up to an additional 2.75 million shares, subject to a stock ownership cap, following any warrant exercise, of 19.99% of PharmAthene's issued and outstanding common stock. During the next three years Panacea Biotec has agreed not to purchase additional shares of PharmAthene stock without the prior written consent of PharmAthene. Panacea Biotec's subsidiary will be granted limited rights to participate in future private financings by PharmAthene to maintain its then current ownership level. In addition, PharmAthene will retain full rights to its proprietary information and technology and full management and operational control.

About the Securities

The securities that are being sold in the transaction have not been
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
3. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
4. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
5. PharmAthene to Present at the BIO CEO & Investor Conference 2008
6. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
7. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
8. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
9. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
10. PharmAthene to Delay Release of Full Year 2007 Financial Results
11. PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... (Nasdaq: PPHM ) today reported completion of patient ... Cotara® in patients with relapsed glioblastoma multiforme (GBM), the ... targeted monoclonal antibody linked to a radioisotope being developed ... specifically targets cells at the center of brain tumors, ...
(Date:12/2/2009)... , - "Bolstering ... Coinciding with the International ... is hosting an international conference in Libreville,(Gabon) on ... The,conference will be attended by government and state ...
(Date:12/2/2009)... World, an event bringing together the leaders in ... biotech and MEMS, announced the December 11th deadline ... in its 14th year, TechConnect World, in association ... and the Clean Technology and Sustainable Industries Organization ...
(Date:12/2/2009)... S*BIO Pte Ltd today announced data presentations on its ... of Hematology 51st Annual Meeting and Exposition in New ... results from the Phase 1 dose-escalation trial of SB1518 ... dose levels ranging from 100 to 600 mg. These ...
Breaking Biology Technology:Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5Libreville International Conference 2-3 June 2010 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5
... 13 /Xinhua-PRNewswire-FirstCall/ -- China Sky One,Medical, Inc. (OTC ... a China based developer, manufacturer, marketer and,international distributor ... financial results for the first quarter,ended March 31, ... compared to First Quarter 2007 (All first ...
... 13 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. (NASDAQ: ANPI ... device company, today announced the appointment of Dr. ... McKinnell is the former Chief Executive Officer and ... Inc. He is currently Chairman of the,Accordia Global ...
... Incorporated,(Nasdaq: VPHM ) today announced that Vincent ... present at the Seventh Annual JMP,Securities Research Conference ... 2008. The,conference is being held at the Ritz-Carlton ... live for investors through, http://www.viropharma.com and available ...
Other Biology Technology:China Sky One Medical, Inc. Announces Record First Quarter 2008 Results 2China Sky One Medical, Inc. Announces Record First Quarter 2008 Results 3China Sky One Medical, Inc. Announces Record First Quarter 2008 Results 4China Sky One Medical, Inc. Announces Record First Quarter 2008 Results 5China Sky One Medical, Inc. Announces Record First Quarter 2008 Results 6China Sky One Medical, Inc. Announces Record First Quarter 2008 Results 7China Sky One Medical, Inc. Announces Record First Quarter 2008 Results 8China Sky One Medical, Inc. Announces Record First Quarter 2008 Results 9China Sky One Medical, Inc. Announces Record First Quarter 2008 Results 10Angiotech appoints Hank McKinnell to its Board of Directors 2
(Date:12/3/2009)... staph infections are caused by many bacterial cells that signal ... quorum sensing because many bacteria must be present to start ... determined that the very first stage of staph infection, when ... in a single cell and that this individual process can ...
(Date:12/3/2009)... past three years in the troposphere (lower atmosphere) over ... which are the first of their kind in the ... 2002 and 2005. , Over recent years, physicists and ... dioxide (CO2) levels, and how these have evolved in ...
(Date:12/2/2009)... more difficult time quitting smoking than those who are ... affect on Latinas odds of quitting smoking. Details of ... & Prevention , a journal of the American Association ... focus on tobacco. , "Acculturation affects smoking cessation differently ...
Breaking Biology News(10 mins):Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 2Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 3CO2 levels rising in troposphere over rural areas 2Acculturation affects smoking cessation success among Latinos 2Online Genetic Testing Appears to Have Benefits 50454 1Online Genetic Testing Appears to Have Benefits 50454 2More than One Third of Docs Say Risk Level Rising for Potential H1N1 Flu Pandemic 50452 1More than One Third of Docs Say Risk Level Rising for Potential H1N1 Flu Pandemic 50452 2More than One Third of Docs Say Risk Level Rising for Potential H1N1 Flu Pandemic 50452 3Vega Picks Tennessee Firm to Assist with Construction of Biomass Plant in Georgia 12856 1Vega Picks Tennessee Firm to Assist with Construction of Biomass Plant in Georgia 12856 2
... the National Institutes of Health have discovered the critical ... of glucose into fat cells. , The study, appearing ... conducted by researchers from the National Institute of Child ... Diabetes and Digestive and Kidney Diseases. , “This finding ...
... of the brain to recover from such injury as stroke ... "talk" to one another using the brain chemical acetylcholine, researchers ... repair Group at UCSD have discovered. Their finding in rats ... leading to the development of drugs or other treatments to ...
... are encased within a protective lipid membrane. The membrane ... transport nutrients, ions, and water into and out of ... each other in the body, and make the nervous ... out nearly all of the membrane proteins in the ...
Other Biology News:NIH Researchers Discover How Insulin Allows Entry of Glucose Into Cells 2Brain-injury rehabilitation depends on acetylcholine circuitry 2